Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Practices in the prescription of antiseizure medications: is it time to change?
Arq Neuropsiquiatr
June 2024
Universidade Estadual de Campinas, Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas SP, Brazil.
The treatment of epilepsy has advanced over the past 30 years through the development of new antiseizure medications (ASMs). Unfortunately, not all of them have been approved yet in Brazil, and many are still underused. When comparing new ASMs to older ones, they are generally not more effective in treating epilepsy.
View Article and Find Full Text PDFImmunosuppressive therapy and oral anticoagulation in kidney transplant recipients: Direct oral anticoagulants versus vitamin-k antagonists.
Eur J Intern Med
January 2024
Division of Renal Medicine, "Fatebenefratelli Isola Tiberina-Gemelli Isola", Rome, Italy. Electronic address:
Background: direct oral anticoagulants (DOACs) are an alternative to conventional antagonist of vitamin-K (AVK). However, immune suppressive drugs (ISDs) may interfere with DOACs pharmacokinetic.
Aim Of This Study: evaluate safety and efficacy profile of DOACs compared to AVK in kidney transplant recipients (KTRs) treated with ISDs.
[Treatment protocol for COVID-19 in patients with and without an indication for hospital admission].
Medicine (Madr)
May 2022
SARS-CoV-2 infection causes a wide spectrum of symptoms with varying degrees of severity, from asymptomatic cases or cases in the form of self-limiting influenza-like illness to cases of rapidly progressing respiratory distress syndrome due to an anomalous immune system response in the form of a cytokine storm. Thrombotic complications are also common. Multiple antiviral treatments have been tested in COVID-19 without favorable outcomes.
View Article and Find Full Text PDFAbsence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation.
Vascul Pharmacol
July 2020
Department of Internal Medicine, Clinical Medicine 1, Padova University Hospital, Italy.
No data are available on rivaroxaban use in renal transplant recipients and on its surmised interaction with immunosuppressants. The aim was to investigate potential interactions between rivaroxaban and immunosuppressants in this setting. Renal transplant recipients with a stable renal function treated with rivaroxaban and tacrolimus with or without everolimus were investigated.
View Article and Find Full Text PDF[Systemic lupus erythematosus with acquired hemophilia A: a case report].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2018
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
Acquired hemophilia A (AHA) is anunusual disease resulting from autoantibodies (inhibitors) against coagulation factor VIII (FVIII) and clinically manifests as bleeding, which sometimes can cause potentially limb-threatening or life-threatening situations. AHA is associated with cancers, auto-immune disorders, infections, dermatologic conditions and certain medications, among which it is commonly secondary to multiple rheumatologic conditions, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), pollymyositis, autoimmune hemolytic anemia and undifferentiated connective tissue disease. In autoimmune diseases, it may be the result of autoantibody producing against FVIII, and some cases of AHA may act as the first manifestation of SLE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!